Stock ACHL ACHILLES THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

All News Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Market Closed - Nasdaq
Other stock markets
 21:30:00 25/06/2024 BST 		5-day change 1st Jan Change
0.8681 USD +1.43% Intraday chart for Achilles Therapeutics plc -3.01% -2.35%
05-22 Achilles Therapeutics Collaborating With Arcturus Therapeutics to Evaluate mRNA Personalized Cancer Vaccines MT
05-22 Achilles Therapeutics plc Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Achilles Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K
PU
Achilles Therapeutics Collaborating With Arcturus Therapeutics to Evaluate mRNA Personalized Cancer Vaccines
MT
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
AQ
Achilles Therapeutics plc Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
CI
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
AQ
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
AQ
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
AQ
Achilles Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8
MT
Chardan Capital Adjusts Achilles Therapeutics Price Target to $6 From $11, Maintains Buy Rating
MT
ADRs Close Lower; Moatable Inc. Declines 33.3%
DJ
Syncona notes investee Achilles's annual loss narrows
AN
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
AQ
Achilles Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Achilles Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
AQ
Achilles Therapeutics plc Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
CI
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
AQ
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
AQ
BofA Securities Downgrades Achilles Therapeutics to Underperform From Buy, Price Target is $0.50
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACHL Stock
  4. News Achilles Therapeutics plc